Lutz Kretschmer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease

Lutz Kretschmer, Reinhard Hilgers, Matthias Möhrle et al. · European Journal of Cancer · 2003 · 134 citations

Medicine, Oncology, Surgery +17

Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection

Lutz Kretschmer, Kai‐Martin Thoms, Sabine Peeters et al. · Melanoma Research · 2008 · 123 citations

Medicine, Oncology, Surgery +14

Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group

Roland Kaufmann, Konstanze Spieth, Ulrike Leiter et al. · Journal of Clinical Oncology · 2005 · 120 citations

Medicine, Oncology, Pharmacotherapy +12

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska et al. · The Lancet Oncology · 2021 · 72 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15